Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Aug;32(8):1799-1803.
doi: 10.1038/s41375-018-0023-2. Epub 2018 Feb 2.

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S Rule  1 , W Jurczak  2 , M Jerkeman  3 , C Rusconi  4 , M Trneny  5 , F Offner  6 , D Caballero  7 , C Joao  8 , M Witzens-Harig  9 , G Hess  10 , I Bence-Bruckler  11 , S-G Cho  12 , C Thieblemont  13 , W Zhou  14 , T Henninger  14 , J Goldberg  14 , J Vermeulen  15 , M Dreyling  16
Affiliations
Clinical Trial

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S Rule et al. Leukemia. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interestSR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ has received research funding from Janssen, Celgene, Abbvie and Gilead. CR has served as an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor and received research funding from Janssen. CJ has served as an advisor for Celgene, Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and received research funding from Roche. MD has served as an advisor and received research funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson & Johnson. The remaining authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Efficacy end points in 3-year follow-up in RAY study: a Progression-free survival for ibrutinib and temsirolimus by prior line of therapy; b Overall survival for ibrutinib and temsirolimus by prior line of therapy; c Duration of clinical response by prior line of therapy in patients randomized to ibrutinib; d Time to second progression or death for ibrutinib and temsirolimus
See this image and copyright information in PMC

References

    1. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:512–8. doi: 10.1200/JCO.2008.16.8435. - DOI - PubMed
    1. IMBRUVICA® [US prescribing information]. Sunnyvale, CA: Pharmacyclics, LLC; Horsham, PA: Janssen Biotech, Inc.; 2017.
    1. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16. doi: 10.1056/NEJMoa1306220. - DOI - PMC - PubMed
    1. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71. doi: 10.1093/annonc/mdx223. - DOI - PubMed
    1. Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international randomised, open-label, phase 3 study. Lancet. 2016;387:770–8. doi: 10.1016/S0140-6736(15)00667-4. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources